Management of Type 1 Diabetes in Pregnancy

Current Diabetes Reports

Volumn 16, Issue 8, 2016, Pages

  Feldman, Anna Z ^a   Brown, Florence M ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

Postpartum; Preconception; Pregnancy; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BREAST FEEDING; CONGENITAL MALFORMATION; CONTINUOUS INFUSION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; EYE EXAMINATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LABOR; LARGE FOR GESTATIONAL AGE; OBESITY; OBSTETRIC DELIVERY; PATIENT COUNSELING; PERINATAL MORTALITY; PREECLAMPSIA; PREGNANCY; PREPREGNANCY CARE; PUERPERIUM; REVIEW; RISK; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; COUNSELING; DIABETES MELLITUS, TYPE 1; FEMALE; PREGNANCY IN DIABETICS;

COUNSELING; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INSULIN; POSTPARTUM PERIOD; PRECONCEPTION CARE; PREGNANCY; PREGNANCY IN DIABETICS;

EID: 84976371073     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-016-0765-z     Document Type: Review

References (142)

1. Jensen DM, Korsholm L, Ovesen P, Beck-Nielsen H, Moelsted-Pedersen L, Westergaard JG, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009;32(6):1046–8.
2. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care. 2007;30:1920–5.
3. Galindo A, Burguillo AG, Azriel S, Fuente PL. Outcome of fetuses in women with pregestational diabetes mellitus. J Perinat Med. 2006;34:323–31.
4. Greene MF, HareJW CJP, Benacerraf BR, Soeldner JS. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology. 1989;39:225–31.
5. Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ. 2004;328:915.
6. Cohen AL, Wenger JB, James-Todd T, et al. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertens Pregnancy. 2014;33(1):81–92. Demonstrates strong association between 1st trimester A1C and risk of preeclampsia. No association was found with 3rd trimester A1C.
7. Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care. 2004;27:2819–23.
8. Casson IF. Pregnancy in women with diabetes--after the CEMACH report, what now? Diabet Med. 2006;23:481–4.
9. Wahabi H, Alzeidan R, Bawazeer G, Alansari L, Esmaeil S. Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2010;10:63.
10. Temple RC, Aldridge VJ, Murphy HR. Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. Diabetes Care. 2006;29:1744–9.
11. Gunton JE, Morris J, Boyce S, Kelso I, McElduff A. Outcome of pregnancy complicated by pre-gestational diabetes – improvement in outcomes. Aust N Z J Obstet Gynaecol. 2002;42:478–81.
12. Pearson DW. The relationship between pre-pregnancy care and early pregnancy loss, major congenital anomaly or perinatal death in type I diabetes mellitus. BJOG: Int J Obstet Gynaecol. 2007;114:104–7.
13. Pregnancy outcomes in the diabetes control and complications trial. Am J Obstet Gynecol. 1996;174:1343-53.
14. Holing EV, Beyer CS, Brown ZA, Connell FA. Why don’t women with diabetes plan their pregnancies? Diabetes Care. 1998;21:889–95.
15. Varughese GI, Chowdhury SR, Warner DP, Barton DM. Preconception care of women attending adult general diabetes clinics--Are we doing enough? Diabetes Res Clin Pract. 2007;76:142–5.
16. Reader D, Thomas AM. Medical nutrition therapy: goals for pregnancy complicated by pre-existing diabetes mellitus. In: Kitzmiller JL, Jovanovic LB, Brown FM, Coustan DR, Reader D, editors. Managing preexisting diabetes and pregnancy: technical reviews and consensus recommendations. Alexandria: ADA; 2008.
17. Garg S, Ampudia-Blasco FJ, Pfohl M. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus. Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2010;16:486–505.
18. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care. 2008;31:1060–79.
19. Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol. 2007;197:447–56.
20. Ranasinghe PD, Maruthur NM, Nicholson WK, et al. Comparative effectiveness of continuous subcutaneous insulin infusion using insulin analogs and multiple daily injections in pregnant women with diabetes mellitus: a systematic review and meta-analysis. J Womens Health (Larchmt). 2015;24(3):237–49.
21. Kitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ratner RE. Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Diabetes Care. 1996;19:514–41.
22. Tennagels N, Werner U. The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem. 2013;119(1):1–14.
23. Pollex E, Moretti ME, Koren G, Feig DS. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother. 2011;45:9–16.
24. Mathiesen ER, Hod M, Ivanisevic M, Duran Garcia S, Brøndsted L, Jovanovic L, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012;35(10):2012–7.
25. Hod M, Mathiesen ER, Jovanovič L, McCance DR, Ivanisevic M, Durán-Garcia S, et al. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med. 2014;27(1):7–13. Detemir is non inferior to NPH in perinatal outcomes in pregnant women with type 1 diabetes.
26. de Valk HW, Visser GH. Insulin during pregnancy, labour and delivery. Best Pract Res Clin Obstet Gynaecol. 2011;25:65–76.
27. James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311(5):507–20. Evidence based JNC8 consensus statement on blood pressure management for patients with preexisting diabetes. Used rigorous evidence based evidence to develop blood pressure treatment recommendations.
28. Bos-Thompson M-A, Hillaire-Buys D, Muller F, et al. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-Up after birth. Ann Pharmacother. 2005;39:157–61.
29. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443–51.
30. Li DK, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ. 2011;343:d5931.
31. Diav-Citrin O, Shechtman S, Halberstadt Y, et al. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol. 2011;31:540–5.
32. Porta M, Hainer JW, Jansson SO, et al. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. Diabetologia. 2011;54:1298–303.
33. Weber-Schoendorfer C, Hannemann D, Meister R, et al. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol. 2008;26:24–30.
34. Magee LA, von Dadelszen P, et al, CHIPS Study Group. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In pregnancy study (CHIPS) trial. BJOG. 2015. Demonstrates that methyldopa is noninferior to labetalol for the treatment of hypertension in pregnancy.
35. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301:587–9.
36. Gordon M, Landon MB, Samuels P, Hissrich S, Gabbe SG. Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy. Obstet Gynecol. 1996;87:401–9.
37. Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med. 1996;335:226–32.
38. Rossing K, Jacobsen P, Hommel E, et al. Pregnancy and progression of diabetic nephropathy. Diabetologia. 2002;45:36–41.
39. Klein BEMS, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care. 1990;13:34–40.
40. The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care. 2000;23:1084–91.
41. Chew EYMJ, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, Conley M, et al. Metabolic control and progression of retinopathy. The diabetes in early pregnancy study. National institute of child health and human development diabetes in early pregnancy study. Diabetes Care. 1995;18:631–7.
42. Rahman WRF, Yassin S, Al-Suleiman SA, Rahman J. Progression of retinopathy during pregnancy in type 1 diabetes mellitus. Clin Exp Ophthalmol. 2007;35:231–6.
43. Cnattingius S, Bergstrom R, Lipworth L, Kramer MS. Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med. 1998;338:147–52.
44. Chung JH, Melsop KA, Gilbert WM, Caughey AB, Walker CK, Main EK. Increasing pre-pregnancy body mass index is predictive of a progressive escalation in adverse pregnancy outcomes. J Matern Fetal Neonatal Med. 2012;0:1–23.
45. Johansson K, Cnattingius S, Näslund I, Roos N, Trolle Lagerros Y, Granath F, et al. Outcomes of pregnancy after bariatric surgery. N Engl J Med. 2015;372(9):814–24. Demonstrates increased risk of small for gestational age risk of infants in non diabetic women who underwent prior bariatric surgery.
46. Middelbeek RJ, James-Todd T, Cavallerano JD, Schlossman DK, Patti ME, Brown FM. Gastric bypass surgery in severely obese women with type 1 diabetes: anthropometric and cardiometabolic effects at 1 and 5 years postsurgery. Diabetes Care. 2015;38(7). Patients with T1DM who have undergone bariatric surgery have reductions in BMI but no improvement in glycemic control.
47. Duntas LH, Orgiazzi J, Brabant G. The Interface between thyroid and diabetes mellitus. Clin Endocrinol. 2011.
48. Bailey BK, Cardwell MS. A team approach to managing preexisting diabetes complicated by pregnancy. Diabetes Educ. 1996;22:111–2. 5.
49. Quevedo SF, Coustan DR. Diabetes and pregnancy. Use of an integrated “team” approach provides the necessary comprehensive care. R I Med J. 1989;72:129–32.
50. Catalano PM, Hauguel-De MS. Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic? Am J Obstet Gynecol. 2011;204:479–87.
51. Lindsay RS, Nelson SM, Walker JD, et al. Programming of adiposity in offspring of mothers with type 1 diabetes at age 7 years. Diabetes Care. 2010;33:1080–5.
52. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. Diabetes Care. 1995;18:611–7.
53. Buinauskiene J, Baliutaviciene D, Zalinkevicius R. Glucose tolerance of 2- to 5-yr-old offspring of diabetic mothers. Pediatr Diabetes. 2004;5:143–6.
54. American Diabetes Association. Management of diabetes in pregnancy. Sec. 12. In standards of medical care in diabetes 2016. Diabetes Care. 2016;39(1):S94–8. An up to date summary of ADA recommendations for the management of preexisting diabetes in pregnancy.
55. Secher AL, Ringholm L, Andersen HU, et al. The effect of real-time continuous glucose monitoring in pregnant women with diabetes. Diabetes Care. 2013;36(7):1877–83. A RCT of CGM as the intervention vs no CGM, which demonstrated no improvement in glycemic control.
56. Law GR, Ellison GT, Secher A, et al. Analysis of continuous glucose monitoring in pregnant women with diabetes: disting temportal patterns of glucose associated with large-for-gestational-age infants. Diabetes Care. 2015;38:1319–24. Different patterns of glucose excursion on CGM that were associated with LGA.
57. Garcia-Patterson A, Gich I, Amini SB, Catalano PM, de Leiva A, Corcoy R. Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. Diabetologia. 2010;53:446–51.
58. McManus RM, Ryan EA. Insulin requirements in insulin-dependent and insulin-requiring GDM women during final month of pregnancy. Diabetes Care. 1992;15:1323–7.
59. Callesen NF, Ringholm L, Stage E, Damm P, Mathiesen ER. Insulin requirements in type 1 diabetic pregnancy: Do twin pregnant women require twice as much insulin as singleton pregnant women? Diabetes Care. 2012;35:1246–8.
60. Kitzmiller JL, Jovanovic L, Brown F, Coustan D, Reader DM, American Diabetes Association, editors. Managing preexisting diabetes and pregnancy: technical reviews and consensus recommendations for care. Alexandria: American Diabetes Association; 2008.
61. Landon MB, Gabbe SG, Piana R, Mennuti MT, Main EK. Neonatal morbidity in pregnancy complicated by diabetes mellitus: predictive value of maternal glycemic profiles. Am J Obstet Gynecol. 1987;156:1089–95.
62. Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER. Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care. 2008;31:9–14.
63. Evers IM, ter Braak EW, de Valk HW, van Der Schoot B, Janssen N, Visser GH. Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. Diabetes Care. 2002;25:554–9.
64. Kimmerle R, Heinemann L, Delecki A, Berger M. Severe hypoglycemia incidence and predisposing factors in 85 pregnancies of type I diabetic women. Diabetes Care. 1992;15:1034–7.
65. Bjorklund AO, Adamson UK, Almstrom NH, et al. Effects of hypoglycaemia on fetal heart activity and umbilical artery Doppler velocity waveforms in pregnant women with insulin-dependent diabetes mellitus. Br J Obstet Gynaecol. 1996;103:413–20.
66. Rizzo T, Metzger BE, Burns WJ, Burns K. Correlations between antepartum maternal metabolism and child intelligence. N Engl J Med. 1991;325:911–6.
67. Zisser HC, Biersmith MA, Jovanovic LB, Yogev Y, Hod M, Kovatchev BP. Fetal risk assessment in pregnancies complicated by diabetes mellitus. J Diabetes Sci Technol. 2010;4:1368–73.
68. Cullen MT, Reece EA, Homko CJ, Sivan E. The changing presentations of diabetic ketoacidosis during pregnancy. Am J Perinatol. 1996;13:449–51.
69. Guo RX, Yang LZ, Li LX, Zhao XP. Diabetic ketoacidosis in pregnancy tends to occur at lower blood glucose levels: case-control study and a case report of euglycemic diabetic ketoacidosis in pregnancy. J Obstet Gynaecol Res. 2008;34:324–30.
70. Schneider MB, Umpierrez GE, Ramsey RD, Mabie WC, Bennett KA. Pregnancy complicated by diabetic ketoacidosis: maternal and fetal outcomes. Diabetes Care. 2003;26:958–9.
71. Bernstein IM, Catalano PM. Ketoacidosis in pregnancy associated with the parenteral administration of terbutaline and betamethasone. A case report. J Reprod Med. 1990;35:818–20.
72. Lindenbaum C, Menzin A, Ludmir J. Diabetic ketoacidosis in pregnancy resulting from insulin pump failure. A case report. J Reprod Med. 1993;38:306–8.
73. Mathiesen ER, Christensen AB, Hellmuth E, Hornnes P, Stage E, Damm P. Insulin dose during glucocorticoid treatment for fetal lung maturation in diabetic pregnancy: test of an algorithm [correction of analgoritm]. Acta Obstet Gynecol Scand. 2002;81:835–9.
74. Curet LB, Izquierdo LA, Gilson GJ, Schneider JM, Perelman R, Converse J. Relative effects of antepartum and intrapartum maternal blood glucose levels on incidence of neonatal hypoglycemia. J Perinatol. 1997;17:113–5.
75. Dudley DJ. Diabetic-associated stillbirth: incidence, pathophysiology, and prevention. Obstet Gynecol Clin N Am. 2007;34:293–307. ix.
76. El Guindy AA, Nabhan AF. A randomized trial of tight vs. less tight control of mild essential and gestational hypertension in pregnancy. J Perinat Med. 2008;36:413–8.
77. von Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. Journal of obstetrics and gynaecology. Canada: JOGC = Journal d’obstetrique et gynecologie du Canada: JOGC. 2002;24:941–5.
78. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet: Off Organ Int Fed Gynaecol Obstet. 2002;77:67–75.
79. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;6:2. A systematic review of antihypertensive drugs that were used to lower blood pressure and prevent progression to more severe disease and improved outcomes in pregnancy.
80. Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407–17. A randomized controlled trial demonstrating that tight vs not tight glucose control is associated with a reduced risk of developing severe hypertension.
81. Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol. 1984;150:831–5.
82. Rothberger S, Carr D, Brateng D, Hebert M, Easterling TR. Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth. Am J Hypertens. 2010;23:1234–40.
83. Firoz T, Magee LA, MacDonell K, Payne BA, Gordon R, Vidler M, et al. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210–8. A systematic review of oral antihypertensive therapy in severe hypertension in pregnancy and postpartum identifying nifedipine and possibly labetalol and methyldopa as suitable options for treatment.
84. Carr DB, Koontz GL, Gardella C, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens. 2006;19:513–9.
85. Davison JM, Noble MC. Serial changes in 24 hour creatinine clearance during normal menstrual cycles and the first trimester of pregnancy. Br J Obstet Gynaecol. 1981;88:10–7.
86. Reece EA, Coustan DR, Hayslett JP, et al. Diabetic nephropathy: pregnancy performance and fetomaternal outcome. Am J Obstet Gynecol. 1988;159:56–66.
87. Kitzmiller JL, Brown ER, Phillippe M, et al. Diabetic nephropathy and perinatal outcome. Am J Obstet Gynecol. 1981;141:741–51.
88. Biesenbach GS, Zazgornik HJ. Influence of pregnancy on progression of diabetic nephropathy and subsequent requirement of renal replacement therapy in female type 1 diabetic patients with impaired renal function. Nephrol Dial Transplant. 1992;7:105–9.
89. Chang LK, Sarraf D. Current and future approaches in the prevention and treatment of diabetic retinopathy. Clin Ophthalmol. 2008;2:425–33.
90. Kaaja R, Loukovaara S. Progression of retinopathy in type 1 diabetic women during pregnancy. Curr Diabetes Rev. 2007;3:85–93.
91. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology. 1981;88:583–600.
92. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:766--85.
93. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.
94. Roseboom TJ, Ravelli AC, van der Post JA, Painter RC. Maternal characteristics largely explain poor pregnancy outcome after hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 2011;156:56–9.
95. Macleod AF, Smith SA, Sonksen PH, Lowy C. The problem of autonomic neuropathy in diabetic pregnancy. Diabet Med: J Br Diabet Assoc. 1990;7:80–2.
96. Abas MN, Tan PC, Azmi N, Omar SZ. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol. 2014;123(6):1272–9. A randomized controlled trial of of ondansetron vs metoclopramide with demonstrating similar antinausea and antiemetic effects, but ondansetron had fewer side effects and reduced ketonuria.
97. Koren G. Treating morning sickness in the United States--changes in prescribing are needed. Am J Obstet Gynecol. 2014;211(6):602–6. A review of ondansetron recommending caution in its use in early pregnancy for the treatment of hyperemesis gravedarum because of possible increased risk of cardiac congenital malformations.
98. Stevens JC, Beard CM, O’Fallon WM, Kurland LT. Conditions associated with carpal tunnel syndrome. Mayo Clinic Proc Mayo Clinic. 1992;67:541–8.
99. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987;59:750–5.
100. Raggi P, Bellasi A, Ratti C. Ischemia imaging and plaque imaging in diabetes: complementary tools to improve cardiovascular risk management. Diabetes Care. 2005;28:2787–94.
101. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
102. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the american diabetes association, a scientific statement of the american heart association, and an expert consensus document of the american college of cardiology foundation. Diabetes Care. 2010;33:1395–402.
103. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26:175–7.
104. Pacheco LD, Saade GR, Hankins G. Acute myocardial infarction during pregnancy. Clin Obstet Gynecol. 2014;57(4):835–43.
105. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol. 1995;75:894-903.
106. Perez A, Wagner AM, Carreras G, et al. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control. Arch Intern Med. 2000;160:2756–62.
107. Chaturvedi N, Fuller JH, Taskinen MR. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care. 2001;24:2071–7.
108. Knopp RH, Warth MR, Carrol CJ. Lipid metabolism in pregnancy. I. Changes in lipoprotein triglyceride and cholesterol in normal pregnancy and the effects of diabetes mellitus. J Reprod Med. 1973;10:95–101.
109. Knopp RH, Van Allen MI, McNeely M, et al. Effect of insulin-dependent diabetes on plasma lipoproteins in diabetic pregnancy. J Reprod Med. 1993;38:703–10.
110. De Groot LD, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and the postpartum: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(8):2543–65.
111. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid: Off J Am Thyroid Assoc. 2011;21:1081–125.
112. Wojcicki JM, Heyman MB. Maternal omega-3 fatty acid supplementation and risk for perinatal maternal depression. J Matern Fetal Neonatal Med: Off J Eur Assoc Perinat Med Fed Asia Oceania Perinatal Societies, Int Soc Perinatal Obstet. 2011;24:680–6.
113. Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med. 2004;351:241–9.
114. Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med. 1990;323:91–6.
115. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the american thyroid association and american association of clinical endocrinologists. Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2011;17:456–520.
116. Persson M, Pasupathy D, Hanson U, Norman M. Birth size distribution in 3,705 infants born to mothers with type 1 diabetes: a population-based study. Diabetes Care. 2011;34:1145–9.
117. Al-Agha R, Firth RG, Byrne M, et al. Outcome of pregnancy in type 1 diabetes mellitus (T1DMP): results from combined diabetes-obstetrical clinics in Dublin in three university teaching hospitals (1995-2006). Ir J Med Sci. 2011.
118. Aman J, Hansson U, Ostlund I, Wall K, Persson B. Increased fat mass and cardiac septal hypertrophy in newborn infants of mothers with well-controlled diabetes during pregnancy. Neonatology. 2011;100:147–54.
119. Mulder EJ, Koopman CM, Vermunt JK, de Valk HW, Visser GH. Fetal growth trajectories in Type-1 diabetic pregnancy. Ultrasound Obstet Gynecol: Off J Int Soc Ultrasound Obstet Gynecol. 2010;36:735–42.
120. Maresh M, Holmes VA, Patterson CP, Diabetes and Pre-eclampsia Intervention Trial Study Goup, et al. Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. Diabetes Care. 2015;38:34–42. A1C > 6% in the 3rd trimester of pregnancy is associated with increasing prevalence of LGA.
121. Combs CA, Gunderson E, Kitzmiller JL, Gavin LA, Main EK. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care. 1992;15:1251–7.
122. Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development--Diabetes in Early Pregnancy Study. Am J Obstet Gynecol. 1991;164:103–11.
123. Mello G, Parretti E, Mecacci F, et al. What degree of maternal metabolic control in women with type 1 diabetes is associated with normal body size and proportions in full-term infants? Diabetes Care. 2000;23:1494–8.
124. Kyne-Grzebalski D, Wood L, Marshall SM, Taylor R. Episodic hyperglycaemia in pregnant women with well-controlled Type 1 diabetes mellitus: a major potential factor underlying macrosomia. Diabet Med. 1999;16:702–6.
125. Murphy HR, Steel SA, Roland JM, et al. Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med. 2011;28:1060–7.
126. Lepercq J, Coste J, Theau A, Dubois-Laforgue D, Timsit J. Factors associated with preterm delivery in women with type 1 diabetes: a cohort study. Diabetes Care. 2004;27:2824–8.
127. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane database of systematic reviews 2006:CD004454.
128. USPSTF. 2014. http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication#Pod11. The USPSTF issued a statement recommending use of ASA 81 mg during weeks 12-36 of pregnancy to help reduce the risk of preeclampsia in women with type 1 and 2 diabetes.
129. Riviello C, Mello G, Jovanovic LG. Breastfeeding and the basal insulin requirement in type 1 diabetic women. Endocrine Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2009;15:187–93.
130. Stuebe A. The risks of not breastfeeding for mothers and infants. Rev Obstet Gynecol. 2009;2:222–31.
131. Dorheim SK, Bondevik GT, Eberhard-Gran M, Bjorvatn B. Sleep and depression in postpartum women: a population-based study. Sleep. 2009;32:847–55.
132. Knip M, Åkerblom HK, Becker D, et al. TRIGR Study Group. Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial. JAMA. 2014;311(22):2279–87. Among infants at risk for type 1 diabetes, the use of a hydrolyzed formula, when compared with a conventional formula, did not reduce the incidence of diabetes-associated autoantibodies after 7 years. These findings do not support a benefit from hydrolyzed formula.
133. Hummel S, Pfluger M, Kreichauf S, Hummel M, Ziegler AG. Predictors of overweight during childhood in offspring of parents with type 1 diabetes: Response to Rodekamp et al. Diabetes Care. 2009;32:e139.
134. Schoen S, Sichert-Hellert W, Hummel S, Ziegler AG, Kersting M. Breastfeeding duration in families with type 1 diabetes compared to non-affected families: results from BABYDIAB and DONALD studies in Germany. Breastfeed Med: Off J Acad Breastfeed Med. 2008;3:171–5.
135. Hawdon JM. Babies born after diabetes in pregnancy: what are the short- and long-term risks and how can we minimise them? Best Pract Res Clin Obstet Gynaecol. 2011;25:91–104.
136. Hummel S, Winkler C, Schoen S, et al. Breastfeeding habits in families with Type 1 diabetes. Diabet Med. 2007;24:671–6.
137. Hartmann P, Cregan M. Lactogenesis and the effects of insulin-dependent diabetes mellitus and prematurity. J Nutr. 2001;131:3016S–20S.
138. Mahmood I, Jamal M, Khan N. Effect of mother-infant early skin-to-skin contact on breastfeeding status: a randomized controlled trial. J Coll Physicians Surg Pak: JCPSP. 2011;21:601–5.
139. Trevathan WR, Smith EO, McKenna J, editors. Evolutionary medicine and health, new perspectives. New York: Oxford University Press; 2007.
140. Food and Drug Administration. Safety. Propylthiouracil tablets. U.S. Department of Health & Human Services. Accessed at http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm209256.htm.
141. Kjos SL. Contraception for women with diabetes, in diabetes in women. In: Tsatsoulis A, Wyckoff J, Brown FM, editors. Pathophysiology and therapy. New York: Humana press; 2009.
142. Huang T, Brown FM, Curran A, James-Todd T. Association of pre-pregnancy BMI and postpartum weight retention with postpartum HbA1c among women with Type 1 diabetes. Diabet Med. 2015;32(2):181–8. Pre pregnancy BMI and postpartum weight retention were positively associated with A1C during the first postpartum year in women with T1DM.